# Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Adults (15-40 Yrs).

> **NCT00697216** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 340 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** HBV-MPL vaccine 208129
- **BIOLOGICAL:** Engerix™-B

## Key facts

- **NCT ID:** NCT00697216
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-03
- **Primary completion:** 1999-03
- **Final completion:** —
- **Target enrollment:** 340 (ACTUAL)
- **Last updated:** 2008-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00697216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00697216, "Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Adults (15-40 Yrs).". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00697216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*